Literature DB >> 19075752

Relaxin and nitric oxide signalling.

M C Baccari1, D Bani.   

Abstract

The peptide hormone relaxin (RLX) has been shown to exert a variety of functions in both reproductive and non-reproductive tissues. The molecular mechanism of RLX on its target cells appears to involve multiple intracellular signalling systems, including the nitric oxide (NO) pathway. NO is an ubiquitous molecule synthesised from L-arginine under the catalytic action of different nitric oxide synthase (NOS) isoforms and its altered production has been reported to be involved in several diseases. RLX has been demonstrated to promote NO biosynthesis by up-regulating NOS expression; its influence on the different NOS appears to depend on the cell type studied. In addition to its physiological roles, RLX has been postulated as a potential therapeutic agent in several diseases. In particular, based on its property to promote NO biosynthesis, RLX may be regarded as a therapeutic tool in diseases characterized pathogenically by an impaired NO production. The aim of the present mini-review is to summarize and discuss the pathophysiological actions of RLX, strictly related to its ability to activate the endogenous NO pathway in reproductive and non-reproductive target organs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19075752     DOI: 10.2174/138920308786733921

Source DB:  PubMed          Journal:  Curr Protein Pept Sci        ISSN: 1389-2037            Impact factor:   3.272


  14 in total

Review 1.  The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease.

Authors:  Jennifer M Sasser
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2013-07-24       Impact factor: 3.619

2.  Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(ω)-nitro-L-arginine methyl ester hypertensive rats.

Authors:  Jennifer M Sasser; Miklos Molnar; Chris Baylis
Journal:  Hypertension       Date:  2011-06-13       Impact factor: 10.190

3.  Relaxin regulates myofibroblast contractility and protects against lung fibrosis.

Authors:  Xiangwei Huang; Ying Gai; Naiheng Yang; Baogen Lu; Chrishan S Samuel; Victor J Thannickal; Yong Zhou
Journal:  Am J Pathol       Date:  2011-10-06       Impact factor: 4.307

Review 4.  Serelaxin in clinical development: past, present and future.

Authors:  Elaine Unemori
Journal:  Br J Pharmacol       Date:  2017-01-29       Impact factor: 8.739

5.  Relaxin peptide hormones are protective during the early stages of ischemic stroke in male rats.

Authors:  Lindsay H Bergeron; Jordan M Willcox; Faisal J Alibhai; Barry J Connell; Tarek M Saleh; Brian C Wilson; Alastair J S Summerlee
Journal:  Endocrinology       Date:  2014-12-02       Impact factor: 4.736

6.  Relaxin activates peroxisome proliferator-activated receptor γ (PPARγ) through a pathway involving PPARγ coactivator 1α (PGC1α).

Authors:  Sudhir Singh; Ronda L Simpson; Robert G Bennett
Journal:  J Biol Chem       Date:  2014-11-11       Impact factor: 5.157

7.  Relaxin signaling activates peroxisome proliferator-activated receptor gamma.

Authors:  Sudhir Singh; Robert G Bennett
Journal:  Mol Cell Endocrinol       Date:  2009-08-25       Impact factor: 4.102

8.  Maternal and Neonatal Complications in Patients With Diminished Ovarian Reserve in In-Vitro Fertilization/Intracytoplasmic Sperm Injection Cycles.

Authors:  Shuang Han; Yiwei Zhai; Qingqing Guo; Yiming Qin; Peihao Liu
Journal:  Front Endocrinol (Lausanne)       Date:  2021-04-29       Impact factor: 5.555

9.  Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury.

Authors:  Massimo Collino; Mara Rogazzo; Alessandro Pini; Elisa Benetti; Arianna Carolina Rosa; Fausto Chiazza; Roberto Fantozzi; Daniele Bani; Emanuela Masini
Journal:  J Cell Mol Med       Date:  2013-09-20       Impact factor: 5.310

10.  Relaxin prevents cardiac fibroblast-myofibroblast transition via notch-1-mediated inhibition of TGF-β/Smad3 signaling.

Authors:  Chiara Sassoli; Flaminia Chellini; Alessandro Pini; Alessia Tani; Silvia Nistri; Daniele Nosi; Sandra Zecchi-Orlandini; Daniele Bani; Lucia Formigli
Journal:  PLoS One       Date:  2013-05-21       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.